FDA adcomm votes in favor of benefit-risk of Grail’s cancer test

An FDA advisory committee spent most of Wednesday raising questions about the utility and effectiveness of Grail’s multi-cancer test Galleri, but ultimately a majority of the panelists voted in favor of the test. The FDA's ...